Lymphoma

SALT LAKE CITY — Chimeric antigen receptor T-cell therapy appeared effective for patients with primary or secondary central nervous system large B-cell lymphoma, according to study results.

A bispecific chimeric antigen receptor T-cell therapy continues to show promising efficacy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma, results of a phase 1/phase 2 trial suggest.

SALT LAKE CITY — Patients with relapsed or refractory large B-cell lymphoma who failed chimeric antigen receptor T-cell therapy achieved durable responses with allogeneic hematopoietic stem cell transplantation, according to study results.

The FDA granted fast track designation to ADI-001 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

The FDA Oncologic Drugs Advisory Committee voted Thursday in favor of randomized data to support future approvals of phosphatidylinositol-3-kinase inhibitors, which are being developed for patients with hematologic malignancies.

An investigational COVID-19 vaccine elicited immune responses in patients with B-cell deficiencies, including those with lymphoma and leukemia, according to recent data.

Infection mitigation with vaccines is essential for patients with hematologic malignancies because they are at increased risk for severe infection, hospitalization and mortality if they contract COVID-19.

An 81-year-old retired teacher presented to the cornea clinic for right eye redness and irritation that started 2 months prior.

Elizabeth Brém, MD, was named a Coltman Fellow to support her work on SWOG’s S1918 trial, designed to assess a reduced-dose chemotherapy regimen in patients aged 75 years or older with newly diagnosed aggressive non-Hodgkin lymphoma.

There are many frustrating aspects to a cancer diagnosis.